Navigation Links
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Date:3/9/2009

aid, "These Phase 3 results in patients infected with the genotype 1 virus, evaluated together with the previously reported Phase 3 results in patients infected with the genotypes 2 and 3 viruses, suggest that albinterferon alfa-2b has the potential to become an important new treatment option for chronic hepatitis C."

"We are encouraged that albinterferon alfa-2b met the primary efficacy endpoint of non-inferiority to peginterferon alfa-2a in both of our pivotal Phase 3 studies," said David C. Stump, M.D., Executive Vice President, Research and Development, HGS. "As we found with the earlier results from ACHIEVE 2/3, the ACHIEVE 1 data show that the rate of sustained virologic response was comparable for the treatment group receiving the 900-mcg dose of albinterferon alfa-2b every two weeks, versus the treatment group receiving the standard dose of peginterferon alfa-2a once weekly. Importantly, the rate of serious and/or severe adverse events was also comparable for these treatment groups. We were pleased to see that serious pulmonary adverse events in the 900-mcg group were infrequent and all resolved with cessation of treatment."

Key Topline Findings from ACHIEVE 1

Treatment Group Receiving Albinterferon Alfa-2b 900-mcg Every Two Weeks, vs. Treatment Group Receiving Peginterferon Alfa-2a 180-mcg Every Week

  • Based on an ITT analysis of the treatment group assigned to receive 900-mcg albinterferon alfa-2b every two weeks, the topline results demonstrate that albinterferon alfa-2b met its primary efficacy endpoint of non-inferiority to peginterferon alfa-2a, with 48.2% (213/442) of patients achieving SVR in the 900-mcg albinterferon alfa-2b treatment group, vs. 51.0% (225/441) in the peginterferon alfa-2a treatment group. The primary analysis, which is adjusted for baseline stratification factors, showed a difference in SVR rates of -1.8% (95% CI -8.1%, 4.5%, p=0.000
    '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Drug Development Program Started Based on CAP(R) Human Cell Line
2. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
9. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
10. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
11. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 The ... a Medical Fitness Center by the Medical Fitness Association, ... centers to achieve their full potential. The Cadence Fitness ... in the western suburbs and second in the Chicagoland ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Inc. (NYSE: HSP ), a global specialty pharmaceutical ... present at two upcoming conferences: , Raymond ... 8, 2011 (Tuesday) – Orlando, Fla.  9:15 a.m. Eastern time ... March 16, 2011 (Wednesday) – Miami, ...
... 2011 Dynatronics Corporation (Nasdaq: DYNT ) today ... 2010. Sales for the quarter ended December 31, ... December 31, 2009. Sales for the six months ended December ... period of the prior year. Net income ...
Cached Medicine Technology:Dynatronics Announces Fiscal Second Quarter Results 2Dynatronics Announces Fiscal Second Quarter Results 3Dynatronics Announces Fiscal Second Quarter Results 4
(Date:4/17/2014)... new study has found that India,s shocking rates of ... farmers who are clinging to tiny smallholdings less ... crops, such as cotton and coffee, that are highly ... a range of previous case studies that point to ... following the ,liberalisation, of the nation,s economy during the ...
(Date:4/17/2014)... Giving patients adrenaline after they suffer a cardiac arrest ... of surviving long-term, according to new research conducted at ... who have a cardiac arrest get adrenaline, which has ... decades," said Dr. Steve Lin, an emergency physician and ... in medical treatment, long-term survival rates of patients who ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... of the embryo. It begins as a glob of identical ... become the cells of our lungs, muscles, nerves and all ... a feat of reverse tissue engineering, Stanford University researchers have ... cells to proliferate and transform into all of the specialized ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... in solid tumors, including long-term patient follow-up, have been ... Issue 232). The data demonstrate robust antibody and T ... with very advanced cancers and suggest that CDX-1401 may ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... involved in cancer, aging , , MONDAY, Sept. 1 (HealthDay ... active region of telomerase, an enzyme involved in both ... repeats of a short DNA sequence to the ends ... damage and loss of genetic information during cell division. ...
... appear to be at higher risk for psychiatric ... children, according to a report in the September ... one of the JAMA/Archives journals. In addition, low-birth-weight ... to have attention problems than suburban low-birth-weight children. ...
... the East coast distribute formula sample packs to new ... concerned about the potential for distributing these packs to ... September issue of Archives of Pediatrics & Adolescent ... practice is changing significantly. , "Packaged as smart diaper ...
... found it predicted outcome months after patient went home ... who sleep during the day while in rehabilitation have ... study, which was expected to be published in the ... the sleeping patterns and other predictors of recovery (e.g., ...
... drug from a biodegradable polymer , , MONDAY, Sept. 1 ... artery-opening, drug-eluting stents appears equally effective as older models ... study shows. , Stents are tiny mesh tubes inserted ... medicines that help prevent reclosure. The latest form of ...
... of a former U.S. soldier whose traumatic brain injuries (TBIs) were ... years after his discharge. The soldier, who suffered several concussions during ... and hearing/visibility issues on a daily basis. , ... ...
Cached Medicine News:Health News:Secrets of Telomerase Revealed 2Health News:Study examines relationship between low birth weight and psychiatric problems in children 2Health News:Hospitals provide formula sample packs while medical organizations encourage breastfeeding 2Health News:Daytime Sleeping Linked to Poor Recovery in Older Patients 2Health News:New Type of Stent Appears Safe, Effective 2Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 2Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 3Health News:LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years 4
Topics include: ECG reading, ACLS (all the latest protocols and pearls), CHF, acute MI, cardiac testing, palpitations, pericarditis, arrhythmias, murmurs, athletes, valvular disease, endocarditis, sy...
Cardiology Core Curriculum fills the gap between the preclinical pathophysiology texts and specialist volumes aimed at cardiologists. It covers clinical cardiology for medical students, cardiology tr...
... Surgery, published by Unbound ... digital resource that combines ... leading edge technology. It ... is specifically engineered to ...
This electronic survival guide provides all the essential information that every surgery intern needs from Day 1 on the wards....
Medicine Products: